Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fast Localized Calibration for Spatial-Spectral Excitation Without Fly-Back Gradients.

Magnetic resonance in medicine·2026
Same author

Contemporary medical management of left ventricular assist device patients: integrating sex-specific perspectives.

Current opinion in cardiology·2026
Same author

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

Circulation·2026
Same author

Global prevalence and mortality of cardiovascular disease by sex and sociodemographic index in young adults (20-39 years): Global burden of disease database 1990-2023.

American journal of preventive cardiology·2026
Same author

Maternal Mortality and Cardio-Kidney-Metabolic Risk Factors Across High-Income Countries.

JACC. Advances·2026
Same author

Association of Substance Use and Psychological Conditions With Adverse Pregnancy Outcomes: A Propensity-Matched Analysis.

JACC. Advances·2026

Related Experiment Video

Updated: Jun 23, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Pregnancy Management and Outcomes with Hypertrophic Cardiomyopathy.

Adhya Mehta1, Sarah Schumacher2, Rebekah Alison Bhansali3

  • 1Inova Health System, Falls Church, Virginia, USA.

CJC Open
|June 22, 2026
PubMed
Summary

Pregnancy in women with hypertrophic cardiomyopathy (HCM) requires careful management due to potential cardiovascular risks. Standardized care and further research are crucial for optimizing outcomes for both mother and fetus.

Keywords:
hypertrophic cardiomyopathypregnancy

Related Experiment Videos

Last Updated: Jun 23, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Area of Science:

  • Cardiology
  • Genetics
  • Maternal-Fetal Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac condition.
  • Increasing diagnosis in women of childbearing age due to genetic testing and screening.
  • Pregnancy can present unique challenges and risks for women with HCM.

Purpose of the Study:

  • To review the specific challenges of managing hypertrophic cardiomyopathy during pregnancy.
  • To highlight the need for standardized protocols and multicentric studies.
  • To improve maternal and fetal outcomes in pregnant women with HCM.

Main Methods:

  • Literature review focusing on hypertrophic cardiomyopathy in pregnancy.
  • Analysis of current management practices and existing research.
  • Identification of knowledge gaps and areas for future research.

Main Results:

  • Most women with HCM tolerate pregnancy, but risks of heart failure and arrhythmias exist.
  • Adverse maternal and fetal outcomes are possible, especially with suboptimal health.
  • Medical therapy is the primary treatment; invasive procedures have limited data in pregnancy.

Conclusions:

  • Management of HCM in pregnancy is complex and varies across centers.
  • There is a significant need for large-scale, multicentric studies.
  • Standardized care protocols are essential to optimize outcomes for pregnant women with HCM and their infants.